Form 4: Lemaitre Vascular Director Reports Equity Award Accruals

Lemaitre Vascular Director Joseph P. Pellegrino JR reported the routine acquisition of dividend equivalent rights tied to his existing restricted stock and performance share unit awards.

Summary

• Joseph P. Pellegrino JR, a Director at Lemaitre Vascular Inc. (LMAT), filed a Form 4 to report changes in his beneficial ownership.
• On September 4, 2025, Mr. Pellegrino acquired various tranches of Dividend Equivalent Rights (DERs).
• These DERs are economically equivalent to one share of LMAT common stock and accrue and vest proportionately with their underlying Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards.
• Specific DER acquisitions include: 0.7211 units (from 12/2/2020 RSU), 1.3714 units (from 12/11/2021 RSU), 2.7926 units (from 12/12/2022 RSU), 2.7926 units (from 12/12/2022 PSU), 3.5808 units (from 12/8/2023 RSU), 4.2906 units (from 12/8/2023 PSU), and 3.4557 units (from 12/6/2024 RSU).
• Following these transactions, Mr. Pellegrino's beneficial ownership of DERs for these specific awards increased to 17.1959, 25.3792, 34.8043, 34.1213, 25.8906, 27.2657, and 11.5606 units, respectively.

Sentiment

Score: 5

Explanation: This is a routine compliance filing reporting the accrual of dividend equivalent rights on existing equity awards, which is a standard part of director compensation and does not indicate new positive or negative operational or financial developments.

Positives

• The accrual of Dividend Equivalent Rights indicates the continued active status and vesting potential of the director's long-term equity compensation awards.

Negatives

• No negative information was disclosed in this routine compliance filing.

Risks

• No specific risks were identified in this Form 4 filing.

Future Outlook

The filing indicates the ongoing vesting schedule for the underlying Restricted Stock Unit and Performance Share Unit awards, to which the reported Dividend Equivalent Rights are proportionally tied.

Industry Context

This Form 4 filing is a standard regulatory disclosure for insider equity transactions within the medical device industry, reflecting routine compensation practices for corporate directors.

Stakeholder Impact

• Shareholders: Provides transparency regarding a director's equity compensation and holdings, confirming the ongoing nature of long-term incentive plans.

Next Steps

• Continued vesting of the underlying Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards.
• Future reporting of any changes in beneficial ownership as required by Section 16(a) of the Securities Exchange Act of 1934.

Key Dates

Keywords

Lemaitre Vascular, LMAT, Joseph P. Pellegrino JR, Director, SEC Form 4, Beneficial Ownership, Dividend Equivalent Rights, RSU, PSU, Equity Compensation, Insider Transaction